May 16th 2023
Jarushka Naidoo, MD, M.B.B.Ch., explains the 5-year-data update from a study investigating single-agent pembrolizumab vs chemotherapy for advanced NSCLC.
The panel reviews data presented at ELCC from EMPOWERLung1 investigating cemiplimab versus chemotherapy in patients with advanced NSCLC.
May 9th 2023
Experts explain recent data updates on single-agent immunotherapy treatment for patient with advanced NSCLC.
Dr Solange Peters reviews data on the efficacy and toxicities of first-line nivolumab and ipilimumab for metastatic non-squamous NSCLC.
May 2nd 2023
Jarushka Naidoo, MD, M.B.B.Ch., explains the debate on the gender differences in advanced NSCLC treatment.
April 26th 2023
Solange Peters, MD, PhD, detail the subgroups of patients with advanced NSCLC and how treatment varies.
April 25th 2023
The panel discusses how patients with advanced NSCLC are sub-grouped in NSCLC and how to approach treatment for each group.
Marina Garassino, MD, reviews the role of PD-L1 testing in advanced non-small cell lung cancer.
November 23rd 2022
Closing their discussion, the panel shares where they think the NSCLC treatment landscape will be in the future, and what to look forward to.
November 16th 2022
The panel explains their approaches to treating patients with mutated NSCLC with immunotherapy.
Dr Johnson reviews data from the ARC-7 trial investigating an anti-PD-L1 plus anti-TGIT combination treatment for advanced NSCLC.
November 9th 2022
Drs Peters and Velcheti provide an overview of the role of anti-TGIT immunotherapies in NSCLC treatment.
Solange Peters, MD, explains the currently available treatment options for patients with advanced NSCLC after progression on immunotherapy.
November 2nd 2022
Melissa Johnson, MD, explains the design and outcomes of the multi-arm POSEIDON study, which featured a combination of 4 agents for the treatment of advanced NSCLC.
Key opinion leaders discuss data from the EMPOWER-Lung-3 study investigating the use of cemiplimab plus chemotherapy in both squamous and non-squamous NSCLC.
October 26th 2022
Dr Velcheti reviews data on the chemoimmunotherapy treatment of squamous NSCLC from the KEYNOTE-407 study.
Dr Vamsidhar Velcheti explains the 4-year data updates to the CheckMate 227 trial, which investigated PD-L1 monotherapy plus chemotherapy for advanced NSCLC.
October 19th 2022
Drs Peters and Johnson discuss recent updates in the treatment of advanced NSCLC with single- and dual-agent immunotherapy regimens.
Dr Melissa Johnson and Dr Myung-Ju Ahn emphasize the importance of a multidisciplinary approach to treatment and biomarker testing for patients with early-stage NSCLC.
October 17th 2022
Closing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.